title: Celgene wagers on Sutro's cell-free platform to ramp up ADCs.
authors.forename: Mark
authors.initials: M
authors.lastname: Ratner
mesh_terms: D018033:Antibodies, Bispecific / Q000096:biosynthesis* / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D002474:Cell-Free System; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D014176:Protein Biosynthesis
chemical_list: D018033:Antibodies, Bispecific; D019496:Cancer Vaccines